Pearl Steinzor

High response rates, strong R0 resection, and low severe adverse events with neoadjuvant therapy plus immunotherapy were identified in a rectal cancer study.

The ustekinumab biosimilar DMB-3115 matched reference therapy in efficacy and safety for moderate to severe plaque psoriasis, according to a phase 3 trial.

Tom Kim, MD, of Sound Long-Term Care Management, discusses how serious illness and care coordination set these ACO patients apart.

From immunotherapy breakthroughs to early-stage scientific advances shaping the next generation of cancer care, these were the top oncology stories from AACR.

A large review identifies 70 safety signals for bimekizumab, confirming known risks while revealing previously unreported adverse events.

Adding ianalumab to eltrombopag significantly prolongs time to treatment failure, boosts 6-month response rates, and improves fatigue for adults with primary ITP.

A low-energy total diet replacement program before colorectal cancer surgery helped patients lose weight safely, improved certain symptoms, and showed cost-effectiveness.

Joanna Rhodes, MD, MSCE, highlights significant racial and ethnic disparities that persist in access to preferred CLL treatments.

Ira Zackon, MD, discusses bispecific antibody use in multiple myeloma among community practices, reflecting real-world treatment trends.

Shayla Bergmann, MD, explains that recombinant von Willebrand factor is both safe and highly effective in controlling perioperative bleeding in children with severe von Willebrand disease.

Updated results highlight the promise of epcoritamab combined with chemotherapy for newly diagnosed DLBCL.

Ivo Carre, PhD, shares subgroup data that points to potential benefit in younger patients with high-risk MDS.

Andrew Evens, DO, MBA, MSc, shares insights from a study on improving prognostic accuracy for advanced-stage Hodgkin lymphoma.

New data in high-risk MDS, emerging menin inhibitors in AML, and evolving care needs in rare bleeding disorders set the stage for major ASH 2025 discussions.

Experts at an Institute for Value-Based Medicine event held October 14, 2025, in Aurora, Colorado, explored advances in neurology care, cross-specialty collaboration, and strategies to improve access and therapy.

A phase 3 trial shows lumateperone added to antidepressant therapy delivers greater symptom improvement and maintains a favorable safety profile in adults with MDD.

A study finds no increased risk of arterial dissections or aneurysms among patients with metastatic colorectal cancer treated with angiogenesis inhibitors.

A national survey shows high overall trust in scientists, but confidence declines steadily with political conservatism.

Children with lower redemption of key WIC foods are more likely to discontinue participation before age 3, study finds.

Pirtobrutinib is now fully approved for CLL/SLL in those previously treated with Bruton tyrosine kinase inhibitors.

Adalimumab significantly reduces activity limitations and boosts work ability and quality of life in patients with psoriasis.

Screening among 45- to 49-year-olds rose nearly 10-fold in hospitals after US guideline updates, but disparities persist.

Shared savings reflects continued growth of long-term-care ACOs in Medicare’s value-based models.

Telehealth has quickly become a central part of the mental health system among younger, higher-income, college-educated, and privately insured patients.

A study identifies tumor stage and stoma status as key drivers of diminished quality of life among patients with colorectal cancer.

Exposure to antibiotics is linked to higher risk of biologic discontinuation in psoriasis, potentially through gut microbiota changes.

Kavita Nair, PhD, FAAN, shares how new therapies and ongoing clinical trials are reshaping the future of neurological care and offering new hope to patients.

Urticaria symptom reduction with remibrutinib was linked with improved quality of life and sleep for patients with chronic spontaneous urticaria.

Remibrutinib shows rapid and sustained relief for chronic spontaneous urticaria, offering a promising oral treatment option for patients.

Randomized clinical trials increasingly support mental health apps as scalable, cost-efficient tools for managing depression and anxiety.